FDA Accelerates Review of Psychedelic Drugs for Mental Health Amid Trump Administration Push

The Food and Drug Administration (FDA) has announced ultra-fast review status for three psychedelic drugs aimed at treating mental health disorders, including depression and post-traumatic stress disorder (PTSD). This move follows President Donald Trump’s recent executive order to expedite research and ease restrictions on psychedelics, a class of hallucinogens currently illegal under federal law.

This development marks a significant step toward potentially approving experimental psychedelic therapies, reflecting growing political and public support, especially among veterans and advocates within the Trump administration. The FDA’s priority review vouchers promise to shorten the regulatory timeline from months to weeks, accelerating access to these novel treatments.

FDA Grants Priority Review to Psychedelic Therapies

The FDA awarded priority review vouchers to two companies developing psilocybin-based treatments for difficult-to-treat depression and a third company working on methylone, a drug related to MDMA, for PTSD. While the FDA did not disclose the companies’ names, the vouchers indicate a commitment to expedite the evaluation process, though they do not guarantee drug approval.

“We owe it to our nation’s veterans and all Americans who are suffering from these conditions to evaluate these potential therapies with urgency.”—FDA Commissioner Marty Makary

Political Momentum Behind Psychedelic Research

President Trump’s executive order and Health Secretary Robert F. Kennedy Jr.’s advocacy have propelled psychedelics into the spotlight. Kennedy’s department aims to make these treatments available within a year for severe psychiatric conditions. Supporters include combat veterans and members of the Make America Healthy Again movement, highlighting a unique coalition backing these substances.

• Trump’s executive order to speed psychedelic research
• Kennedy’s goal to approve psychedelics within one year
• Veterans and political allies championing the cause
• FDA’s Commissioner’s National Priority Voucher program under scrutiny for political favoritism

New Psychedelic Drug Trials and Safety Considerations

In addition to psilocybin and methylone, the FDA authorized initial testing of a drug related to ibogaine, a potent psychedelic derived from an African shrub, for alcohol use disorder. Although ibogaine can cause serious side effects, the new drug, developed by DemeRx, is designed to minimize hallucinogenic effects and risks.

“Every grant proposal that I submitted to (the National Institute on Drug Abuse) was rejected. I couldn’t get that funding and that’s why ibogaine didn’t advance in the 1990s.”—Deborah Mash, neurologist and founder of DemeRx

The Role of Influencers and Future Outlook

High-profile figures like podcaster Joe Rogan have influenced the administration’s focus on psychedelics. Rogan’s direct communication with President Trump reportedly helped bring ibogaine into the regulatory conversation. Meanwhile, Silicon Valley investors and tech billionaires such as Peter Thiel are funding companies racing to develop FDA-approved psychedelic treatments.

As psychedelics move closer to mainstream acceptance, the FDA’s accelerated review process and political backing suggest a transformative shift in mental health treatment options. However, the path forward will require balancing innovation with safety and regulatory scrutiny.